No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVS240517P95000
- 0.05
- -0.05-50.00%
15min DelayClose May 10 16:00 ET
0.29High0.05Low
0.29Open0.10Pre Close22 Volume583 Open Interest95.00Strike Price182.00Turnover27.96%IV-7.00%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.0312Delta0.0174Gamma2042.00Leverage Ratio-0.0174Theta-0.0006Rho-63.75Eff Leverage0.0102Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 64369.0 Shares on Sell Side
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).TAMARACK is being conducted in previously treated patients with metastatic
Express News | Novartis Gets FDA Breakthrough Designation For Scemblix
Express News | NYSE Order Imbalance 55282.0 Shares on Sell Side
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
Researchers at Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind have developed AlphaFold 3, an new artificial intelligence (AI) model.AlphaFold 3 can predict the structure and interactions
Cagent Vascular Appoints Chairman Brian Walsh to Expanded Role as Chief Executive Officer
Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the Board since March 2018 and will continue in this
Comments
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Recent M&A activities💰 in January:
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
$Ambrx Biopharma(AMAM.US$ acquisition by $Johnson & Johnson(JNJ.US$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US$
$Harpoon Therapeutics(HARP.US$ acquisition by $Merck & Co(MRK.US$
Calypso Biotech acquisition by $Novartis AG(NVS.US$
What companies will be next? 🤔
1
Since last October, the biotech sector has been showing signs of recovery. This trend was underscored by the S&P Biotechnology Select Industry Index, which surged by 4.69% yesterday and jumped to a new high since Aug 2022.On 8 Jan, J&J, Merck, and Novartis each announced a series of acquisition deals, many of which featured premiums of over 100%:
● $Johnson & Johnson(JNJ.US$ has agreed to pay $2 billion in cash for antib...
● $Johnson & Johnson(JNJ.US$ has agreed to pay $2 billion in cash for antib...
10
Read more